An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired venal function

British Journal of Clinical Pharmacology, Supplement

Volumn 46, Issue 1, 1998, Pages 56-60

  Tiseo, P J ^a   Foley, K ^b   Friedhoff, L T ^a  

^a EISAI INC   (United States)

^b EISAI CO LTD   (Japan)

Author keywords

Alzheimer's disease; Donepezil; Renal impairment

Indexed keywords

CREATININE; DONEPEZIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; DRY EYE; FATIGUE; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY DISEASE; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; ULTRAVIOLET SPECTROSCOPY;

ADMINISTRATION, ORAL; ADULT; AGED; ANALYSIS OF VARIANCE; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INDANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PIPERIDINES;

EID: 0032420657     PISSN: 02643774     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. 14C). J Label Compounds Radiopharm 1989; XXVII: 835-839.
2. Sugimoto H, Tsuchiya Y, Sugumi H et al. Novel piperidine derivatives. Synthesis and anti-cholinesterase activity of 1-benzyl-4-[2-(N-benzoylamino)ethyl]piperidine derivatives. J Med Chem 1990; 33: 1880-1887.
3. Rogers SL, Yamanishi Y, Yamatsu K. E2020 - the pharmacology of a piperidine cholinesterase inhibitor. In Cholinergic Basis for Alzheimer Therapy, eds Becker R, Giacobini E. Boston: Birkhäuser, 1991: 314-320.
4. Sherman K. Pharmacodynamics of oral E2020 and tacrine in humans: novel approaches. In Cholinergic Basis for Alzheimer Therapy, eds Becker R, Giacobini E. Boston: Birkhäuser, 1991: 321-328.
5. Rogers SL, Friedhoff LT, the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996; 7: 293-303.
6. Rogers SL, Farlow MR, Doody RS, Mohs R, Fnedhoff LT, the Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-145.
7. Rogers SL, Doody RS, Mohs R, Friedhoff LT, the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158: 1021-1031.
8. Tisco PJ, Perdomo CA, Friedhoff LT. Metabolism and elimination of C-doncpezil in healthy volunteers: a single-dose study. Br J Clin Pharmacol 1998; 46 (Suppl. 1): 19-24.
9. Lee JW, Rogers SL, Friedhoff LT, Stiles MR, Cooper NM. Validation and application of an HPLC method for the determination of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl] methyl piperidine HCl (E2020) in human plasma. Pharm Res 1992; 9: S350.
10. Rogers SL, Cooper NM, Sukovaty R, Pederson JE, Lee JN, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 1998; 46 (Suppl. 1): 7-12.
11. Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 1998; 46 (Suppl. 1): 13-18.